Real-time Estimate
Cboe BZX
12:39:39 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
0.613
USD
|
-0.64%
|
|
-10.26%
|
-60.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
26.71
|
59.87
|
99.49
|
28.52
|
114.9
|
53.23
|
-
|
Enterprise Value (EV)
1 |
26.71
|
59.87
|
99.49
|
28.52
|
114.9
|
53.23
|
53.23
|
P/E ratio
|
-
|
-
|
-
|
-1.33
x
|
-1.76
x
|
-2.22
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
23.9
x
|
3.71
x
|
1.92
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
23.9
x
|
3.71
x
|
1.92
x
|
EV / EBITDA
|
-0.98
x
|
-2.72
x
|
-4.13
x
|
-1
x
|
-2.35
x
|
-0.89
x
|
-0.91
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
171,270
|
349,170
|
715,156
|
715,156
|
1,086,589
|
1,199,089
|
-
|
Reference price
2 |
0.1559
|
0.1715
|
0.1391
|
0.0399
|
0.1058
|
0.0444
|
0.0444
|
Announcement Date
|
3/12/20
|
2/23/21
|
3/16/22
|
3/22/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
4.8
|
14.36
|
27.77
|
EBITDA
1 |
-27.17
|
-21.99
|
-24.07
|
-28.5
|
-48.99
|
-59.8
|
-58.8
|
EBIT
1 |
-28.11
|
-22.93
|
-24.78
|
-29.16
|
-49.69
|
-39.24
|
-30.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,035.29%
|
-273.16%
|
-109.46%
|
Earnings before Tax (EBT)
1 |
-25.45
|
-30.02
|
-27.05
|
-24.95
|
-60.61
|
-47.78
|
-37.65
|
Net income
1 |
-25.45
|
-30.02
|
-27.05
|
-24.95
|
-60.61
|
-47.28
|
-36.65
|
Net margin
|
-
|
-
|
-
|
-
|
-1,262.79%
|
-329.12%
|
-131.96%
|
EPS
2 |
-
|
-
|
-
|
-0.0300
|
-0.0600
|
-0.0200
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
2/23/21
|
3/16/22
|
3/22/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
4.8
|
0.34
|
0.47
|
0.81
|
4.69
|
6.91
|
EBITDA
1 |
-11.97
|
-11.6
|
-6.05
|
-6.424
|
-5.906
|
-7.461
|
-13.37
|
-6.925
|
-8.211
|
-8.597
|
-9.717
|
-18.31
|
-12.14
|
-18.54
|
-16.8
|
-17.1
|
-33.9
|
-13.7
|
-12.2
|
EBIT
|
-
|
-
|
-6.217
|
-6.598
|
-6.079
|
-7.602
|
-
|
-7.078
|
-8.398
|
-8.856
|
-9.915
|
-18.77
|
-12.36
|
-18.57
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-386.79%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.42
|
-17.03
|
-5.716
|
-4.304
|
-4.93
|
-7.443
|
-12.37
|
-6.847
|
-5.731
|
-12.16
|
-18.54
|
-30.71
|
-16.2
|
-13.88
|
-21
|
-21.3
|
-42.3
|
-17.9
|
-16.5
|
Net income
1 |
-13.42
|
-17.03
|
-5.716
|
-4.304
|
-4.93
|
-7.443
|
-12.37
|
-6.847
|
-5.731
|
-12.16
|
-18.54
|
-30.71
|
-16.2
|
-13.88
|
-21
|
-21.3
|
-42.3
|
-17.9
|
-16.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-289.25%
|
-6,176.47%
|
-4,531.91%
|
-5,222.22%
|
-381.66%
|
-238.78%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0200
|
-
|
-0.0200
|
-0.0100
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
8/18/21
|
11/18/21
|
3/16/22
|
5/11/22
|
8/16/22
|
8/16/22
|
11/15/22
|
3/22/23
|
5/24/23
|
8/30/23
|
8/30/23
|
11/20/23
|
3/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
2/23/21
|
3/16/22
|
3/22/23
|
3/26/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +7.75% | 113B | | +10.95% | 106B | | +0.41% | 22.27B | | -11.88% | 22.22B | | -5.99% | 19.43B | | -37.36% | 17.87B | | -5.91% | 17.24B | | +6.86% | 14.29B | | +35.94% | 12.52B |
Bio Therapeutic Drugs
|